Studies concerning the effect of proteasome inhibitors on ERα content in ER+ cultures of breast cancer cells showed that bortezomib, an inhibitor of chymotrypsin-like proteasome activity, decreased the proteolysis of the receptor for several hours [99]. Here, ESR1 is linked to breast cancer.